New drug aims to tame gluten reaction in celiac disease
Disease control
Stopped early
This study tested an experimental drug called KAN-101 in people with celiac disease. The goal was to see if it could safely reduce the immune response to gluten. The trial included 128 participants and was split into phases to check safety and how the body processes the drug. How…
Phase 1/2 • Sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC